Skip to main content
SpringerLink
Log in

Cetuximab cost effective for mCRC with wild-type RAS gene

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2013 British pounds

  2. National Institute for Health and Care Excellence

Reference

  • Harty G, et al. Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work. Applied Health Economics and Health Policy : 9 Jun 2018. Available from: URL: https://doi.org/10.1007/s40258-018-0395-5

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cetuximab cost effective for mCRC with wild-type RAS gene. PharmacoEcon Outcomes News 806, 6 (2018). https://doi.org/10.1007/s40274-018-5049-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-5049-1

Search

Navigation